October 21, 2024
2 min watch
Save
VIDEO: Dose expansion study performed on novel BCL-2 inhibitor for acute myeloid leukemia
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Noah Merin, MD, PhD, discusses the results of a Chinese study into the use of venetoclax in the treatment of acute myeloid leukemia and non-Hodgkin lymphoma, presented at ESMO Congress.
Merin, director of the leukemia program at Cedars-Sinai Medical Center, highlighted the study, which was a dose escalation expansion study of a class of drug that AML has already displayed responsiveness to.
“[TQB3909] looks like a plausible member of the BCL 2 class,” Merin said.
Reference:
- Qi J, et al. Abstract 800MO. Presented at European Society for Medical Oncology Congress; Sept. 13-17; Barcelona, Spain.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Merin reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.